{"name":"Texas Retina Associates","slug":"texas-retina-associates","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Active bevacizumab and Active dexamethasone","genericName":"Active bevacizumab and Active dexamethasone","slug":"active-bevacizumab-and-active-dexamethasone","indication":"Retinal diseases with abnormal neovascularization and inflammation (e.g., diabetic macular edema, retinal vein occlusion)","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Eylea","genericName":"Eylea","slug":"eylea","indication":"Branch retinal vein occlusion with macular edema","status":"marketed"}]}],"pipeline":[{"name":"Active bevacizumab and Active dexamethasone","genericName":"Active bevacizumab and Active dexamethasone","slug":"active-bevacizumab-and-active-dexamethasone","phase":"phase_2","mechanism":"This combination uses bevacizumab to inhibit vascular endothelial growth factor (VEGF) and reduce abnormal blood vessel formation, while dexamethasone suppresses inflammation in the eye.","indications":["Retinal diseases with abnormal neovascularization and inflammation (e.g., diabetic macular edema, retinal vein occlusion)"],"catalyst":""},{"name":"Eylea","genericName":"Eylea","slug":"eylea","phase":"marketed","mechanism":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","indications":["Branch retinal vein occlusion with macular edema","Central retinal vein occlusion with macular edema","Exudative age-related macular degeneration","Macular edema due to diabetes mellitus","Metastasis from malignant tumor of colon"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE1vYVAydV9YNmhBQVBLOWVMVmlQS1dyVk1pU2hSajhqWmhydldLTGJ2UTIwTV9JZWtLVzZUeXZ2SFg1YzJfS1V1aGJRdGNSM0RaMnpuMlBkZG1MY1RXcXc?oc=5","date":"2026-03-03","type":"pipeline","source":"Ophthalmology Times","summary":"Special Report - Ophthalmology Times","headline":"Special Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQQVpobkJHUFdfRmVwbmVRT0tNUDZlZlJkdW9kSkpNR1J5UGZfUEI5MncxeEphYURkNHBKN25TY3NodUM1MzdLNWdTMGdvQ25qWW96aVBsOVk1endHSVhFT0F3TGxTaUZrTXZ4YnRhdHVhUzFmYmVMYUo4cHVfbTNUcHp1YlVPUi1wbFN1ZHFBRENRMW5nekdqLU1RcTRGRE1aVG94bVB5VmRZVlhMTk9aSmZR?oc=5","date":"2026-03-03","type":"trial","source":"Ophthalmology Times","summary":"Advancing geographic atrophy care: Long-term data and real-world insights - Ophthalmology Times","headline":"Advancing geographic atrophy care: Long-term data and real-world insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPcDIyMDhZNlRQV21BVXRmZWdNZ0h1cmluQ2lQc0h4cjVJbHNqQWI4a0FwSXdRc2NTVjJHODd0c1U1LVNVYXFjbmdUNEl3YnJhYjF3M0RrS0FKX2kzR3hGdnV6bjk1N0NjQ2k5bHhkOHJqdnhkaWJZc3VFbk5vVVdKNjZkLTVWMjZEbTJZdGhQVGotSXJtT3lUUUhTQ1RlX05aZHZVZXlPeHFuU2NOTkFvZGxjTQ?oc=5","date":"2026-01-05","type":"pipeline","source":"modernretina.com","summary":"Treating MacTel: First identify patient candidates and appropriate eye selection - modernretina.com","headline":"Treating MacTel: First identify patient candidates and appropriate eye selection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQUTdpOVY1a19ZZkZrMDVSR0dQN0g1TDJSMlJFYi1iS1lacnNIR2p0ODNwUm5Rd3JlMVVMTTNzTW5OSjZlQm5EM1gwYV9oRU1EX0V3WUdWNnFBeDJwdF9fazctaDZfWDVMUXllclBKeHpvQTg5TllMWE9iZER1dEVKdDhYYUo2VmlGMlNzcVJjQjdnTU5rS1Vn?oc=5","date":"2025-10-21","type":"pipeline","source":"Pharmaceutical Technology","summary":"AAO 2025: EYP-1901 continues to show promise in DME and wAMD - Pharmaceutical Technology","headline":"AAO 2025: EYP-1901 continues to show promise in DME and wAMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPZExQaVhPcnI0bE1PRkZPX2w5UTBzY3lkZ2RGMllYZTdNay1Jc1hNbGdmUEI2WldXQ1poUVozYldaTTh4NGJUbzF3eGJaYURic1oxQ0Qyd2kyNW9VcjJTd2IzUmhmY2JUSDI1RjlERE5sbXNseUhoYjhkMl94b0R1c0ZGT2ljblVOdWNNbzFfVDh6eXVvME1yNktRY0YyNUNyWWtJUHZKOA?oc=5","date":"2025-10-06","type":"deal","source":"The Business Journals","summary":"Eye care group acquired by Texas business - The Business Journals","headline":"Eye care group acquired by Texas business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPTlBYdVNSNHBqOEN5ZVZpRXhXSDNVNTh1Q0F3UWNteVJPbVhJekNCWXdKMlgyTm9SOE5sVUtITG0weFlwcFlwSWtSWm1JWU5LUGxsT01EaE5LY3FobEV3MkFtSkM5bzdDMjhyQU84aW5sb1F4OVhzblBrTkhVOW14N081eVVSYXpHd1M1b2V5a1M5T25PMUh0bVVGd1NhQUkwa3pndDhBYURJT1Uwbm1sblVn?oc=5","date":"2025-08-20","type":"pipeline","source":"Dallas News","summary":"UTSW researchers find link between sex hormones and rare eye disease - Dallas News","headline":"UTSW researchers find link between sex hormones and rare eye disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFB5TmYxa2NaRUFkeFFsWTI1aUFwVjh6Qm1xWUtSaXktYXVwa1VncExHMlBYRUs4WFVhQWJkaFE1VlZ3ODNmRTFMVkx4YmxjTkE0TWVXNzdtenFqbWtIME1JcGx4dzRPSmM?oc=5","date":"2025-08-05","type":"pipeline","source":"MedPage Today","summary":"Retina Specialists Sound the Alarm on Loss of Copayment Support for AMD Drugs - MedPage Today","headline":"Retina Specialists Sound the Alarm on Loss of Copayment Support for AMD Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQX1dmM1V4ZGVPaU1QWjEwcWVkOGxlNGFlS2FZejZhWExHUHFDMDZwS21RMzNLZTBxUW5xUC14YnpJY0hURkhhbF9jS2N5aFpsc0lYaTVyR1g1UVFKNXdUV1I3R09BblJkRTVjdEZEZWJ5TUlROFhOVFB0VGxab0M5Uk1NbXhrUU9pNDZZVVV3VlpiU01HNWJqWlFIZlBqUkJDRjJxS3g0aTMtSFlacWFwSzdfc2Nod3lYMkVoVGtWRmFucXFRUVE?oc=5","date":"2025-07-15","type":"trial","source":"Healio","summary":"VIDEO: Duravyu in phase 3 trials after encouraging phase 2 results in wet AMD - Healio","headline":"VIDEO: Duravyu in phase 3 trials after encouraging phase 2 results in wet AMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1oaXFZckF1akR0ZzZ2c2plYlJHM09tQ0pYNkdzX1d4cjhJSF96ZTYybEFrV2VvMklVbUJ0ZTkyaWgzeVEyUDItalN5LXUzcG8tLXZUbldYNEhrWUdfdHpF?oc=5","date":"2024-12-11","type":"trial","source":"Nature","summary":"Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study | Eye - Nature","headline":"Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE stu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQcGlrT1BhNTZDY3hnZ05oNXdPVEg5VldIclpQeF9vTzJIVi11MVEtSU5YVXBPc2o1TmZHU3hLTVdMRVc0UnVybEN1XzVUWGZyS2ZYeVZ3Y3pYQWxsWXlDdG1ZSDY5U0sydXVudTdNMXAzOXZEUjBacDk2Z3dueXdsclJjdlVreGhVMDdfM2Z2Mzk1aXhMQTB5ZlYzS25scVYzQy1QY3laUFh5Tlpab0FWY3k5TVFLQUhtNkZWOUhLNGJQU050SHI4TU5rUnVJYm5RRXlXcFU3VWJjWm40S1ZkQlVaSzRVNG5ZdHU1STF3?oc=5","date":"2024-10-24","type":"trial","source":"Ophthalmology Times","summary":"EyePoint Pharmaceuticals announces first patient dosed in global Phase 3 LUGANO clinical trial of Duravyu for wet AMD - Ophthalmology Times","headline":"EyePoint Pharmaceuticals announces first patient dosed in global Phase 3 LUGANO clinical trial of Duravyu for wet AMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB0RXRadEdJcjBERi1SLXd4bnVEWkpHc2ZpYllaT3pUSTBvVmVzeENleHVaczV6Vkd3cnVqdlV4eDhkRVVOQUw2ZE5HREtqWEVvd3FJTzRiZzNlQnZJclFZ?oc=5","date":"2024-04-15","type":"pipeline","source":"Nature","summary":"Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy - Nature","headline":"Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPeEFmTTdRNzhuVWl3SHRKZGJrRmVDbWxZdkg2UjEzX25vX2xRUHhyTVJLMndVOTVLdGZWdEVNZjkwRldDekUxcVZRWVNTcHRIaW04Y3FxaHB6XzFLZldkb096RnBkTC0wV1FqcG1xWUZZeWwxOHZ3MU1oX1ZyOG9yVEVHaTRnMVlfWGs3Wg?oc=5","date":"2021-08-16","type":"pipeline","source":"modernretina.com","summary":"Combination therapy lowers treatment burden in DME - modernretina.com","headline":"Combination therapy lowers treatment burden in DME","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}